Drug Trial Radar · NCT06257875
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Oct 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
156
Actual
Start
Mar 23, 2024
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Feb 14, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). The purpose of this study is to assess how safe and effective lutikizumab is in adult participants with moderate to severe UC and how lutikizumab compares to adalimumab in the treatment of UC. Adverse events and changes in disease activity will be assessed. Lutikizumab is an investigational product being developed for the treatment of moderate to severe UC. Participants are placed in groups called treatment arms. Each group receives a different treatment. In the Induction Period, participants will be randomized into 1 of 3 arms receiving lutikizumab Dose 1, lutikizumab Dose 2, or adalimumab. In the Maintenance Period, participants who responded to lutikizumab will be randomized into 1 of 2 arms of lutikizumab maintenance and participants who responded to adalimumab will continue to receive adalimumab. All participants who did not achieve clinical response per modified Mayo Score at the end of the Induction period will receive lutikizumab. Around 200 adult participants with UC will be enrolled at approximately 200 sites worldwide. During the 12 week Induction Period, participants will be randomized to receive intravenous (IV) and subcutaneous (SC) lutikizumab or SC adalimumab. At the 12 week mark, participants who are on lutikizumab who have responded to treatment will be re-randomized to receive SC lutikizumab at different intervals until Week 52. Participants who are on adalimumab who are responding to treatment will continue to receive adalimumab. Participants who do not respond to treatment will receive SC lutikizumab. Participants who complete the Week 52 visit and in whom therapeutic benefit to study drug is confirmed by the investigator may roll over into an optional, 52-week long-term extension (LTE). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Ulcerative Colitis
Interventions
LutikizumabDrug
Subcutaneous (SC) Injection
LutikizumabDrug
Intravenous (IV) Infusion
AdalimumabDrug
SC Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants who Achieve Endoscopic ImprovementTime frame: Week 12
- Number of Participants with Adverse Events (AEs)Time frame: Up to approximately Week 104
Locations
191 sites in 30 countries. Site status is shown where the registry gives one.
Gastro SB /ID# 258331
Chula Vista, California
Southern California Res. Ctr. /ID# 258391
Coronado, California
Newport Huntington Medical Group /ID# 258371
Huntington Beach, California
Om Research LLC /ID# 261383
Lancaster, California
UC Irvine Health /ID# 259824
Orange, California
University of Colorado Hospital /ID# 258388
Aurora, Colorado
Research Associates of South Florida, LLC /ID# 259813
Coral Gables, Florida
University of Florida College of Medicine /ID# 260402
Gainesville, Florida
Auzmer Research /ID# 260940
Lakeland, Florida
Atlantic Medical Research /ID# 258507
Margate, Florida
Homestead Associates in Research /ID# 260392
Miami, Florida
University of Miami /ID# 258396
Miami, Florida
JD Medical Group, LLC /ID# 261235
Miami, Florida
Gastroenterology Group Naples /ID# 258346
Naples, Florida
AdventHealth Medical Group Blood & Marrow Transplant at Orlando /ID# 260945
Orlando, Florida
GCP Clinical Research, LLC /ID# 260401
Tampa, Florida
Atlanta Ctr. for Gastro /ID# 259275
Decatur, Georgia
Gastroenterology Associates of Central Georgia, LLC /ID# 258359
Macon, Georgia
Gastroenterology Consultants, P.C /ID# 258352
Roswell, Georgia
Northwestern Medicine - Northwestern Memorial Hospital /ID# 259592
Chicago, Illinois
University of Chicago Medical Center /ID# 258491
Chicago, Illinois
IU Health University Hospital /ID# 260398
Indianapolis, Indiana
Univ Kansas Med Ctr /ID# 258489
Kansas City, Kansas
Louisiana Research Center, LLC /ID# 258330
Shreveport, Louisiana
Massachusetts General Hospital /Id# 259817
Boston, Massachusetts
Clin Res Inst of Michigan, LLC /ID# 258386
Chesterfield, Michigan
Clin Res Inst of Michigan, LLC /ID# 259267
Chesterfield, Michigan
Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinic /ID# 258493
Wyoming, Michigan
Mayo Clinic - Rochester /ID# 258402
Rochester, Minnesota
Univ New Mexico /ID# 258490
Albuquerque, New Mexico
NY Scientific /ID# 260937
Brooklyn, New York
NYU Langone Long Island Clinical Research Associates /ID# 258504
Lake Success, New York
Weill Cornell Medicine/NYP /ID# 258953
New York, New York
Columbia University Medical Center /ID# 258496
New York, New York
Atrium Health /ID# 258506
Charlotte, North Carolina
DJL Clinical Research, PLLC /ID# 259465
Charlotte, North Carolina
Atrium Health Wake Forest Baptist Medical Center /ID# 260387
Winston-Salem, North Carolina
Plains Clinical Research Center, LLC /ID# 258502
Fargo, North Dakota
Digestive Disease Specialists /ID# 258499
Oklahoma City, Oklahoma
Digestive Health Associates of Texas (DHAT) Research Institute - Garland /ID# 258358
Garland, Texas
Showing 40 of 191 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.